第一上海(00227.HK)發售股份獲有效接納48.8%
格隆匯9月17日丨第一上海(00227.HK)公吿,於2021年9月10日下午四時正(即接納發售股份及繳付股款的最後時限),已就合共1.38億股發售股份收到合共33份相關申請表格項下的暫定配發的有效接納,佔公開發售項下可供合資格股東認購的發售股份總數約48.8%。根據認購及接納結果,公開發售認購不足額為1.45億股發售股份,佔公開發售項下可供合資格股東認購的發售股份數目約51.2%。
公開發售及根據配售協議配售未獲認購股份分別已於2021年9月17日及9月16日完成。發售股份預計將於2021年9月21日上午九時正於聯交所開始買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.